Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IMPACT OF PROTEASE INHIBITORS ON AIDS-DEFINING EVENTS AND HOSPITALIZATIONS IN 10 FRENCH AIDS REFERENCE CENTERS
Autore:
MOUTON Y; ALFANDARI S; VALETTE M; CARTIER F; DELLAMONICA P; HUMBERT G; LANG JM; MASSIP P; MECHALI D; LECLERCQ P; MODAI J; PORTIER H;
Indirizzi:
CTR HOSP,SERV MALAD INFECT F-59208 TOURCOING FRANCE CHU,SERV MALAD INFECT RENNES FRANCE HOP ARCHET,SERV MALAD INFECT NICE FRANCE HOP CHARLES NICOLLE,SERV MALAD INFECT ROUEN FRANCE HOP CIVIL,CLIN MED A STRASBOURG FRANCE HOP RANGEUIL,SERV MED INTERNE A TOULOUSE FRANCE CTR HOSP,SERV MED INTERNE ST DENIS REUNION CHU,SERV MALAD INFECT GRENOBLE FRANCE HOP ST LOUIS,SERV MALAD INFECT PARIS FRANCE HOP BOCAGE,SERV MALAD INFECT DIJON FRANCE
Titolo Testata:
AIDS
fascicolo: 12, volume: 11, anno: 1997,
pagine: 101 - 105
SICI:
0269-9370(1997)11:12<101:IOPIOA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Keywords:
THERAPY; DISEASE PROGRESSION; HEALTH CARE; ECONOMICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
5
Recensione:
Indirizzi per estratti:
Citazione:
Y. Mouton et al., "IMPACT OF PROTEASE INHIBITORS ON AIDS-DEFINING EVENTS AND HOSPITALIZATIONS IN 10 FRENCH AIDS REFERENCE CENTERS", AIDS, 11(12), 1997, pp. 101-105

Abstract

Objective: To assess the clinical and economic consequences of the use of protease inhibitors in the treatment of HIV infection. Design: Multicentric, observational, retrospective cohort study. Setting: Ten AIDS reference centres in France. Patients: All patients followed in each centre from September 1995 through October 1996. Main outcome measures: AIDS-defining events, death, health-care resources use, administration of antiretroviral therapy. Results: Data from 7749 patients in 10centres showed a drop in hospitalization days by 35%, new AIDS cases by 35%, and deaths by 46%. In the same period, the proportion of patients receiving antiretrovirals rose from 36 to 53% including highly active antiretroviral therapy (HAART), which rose from 0.3 to 18%. Overall cost evaluation showed a slight increase of monthly treatment cost of US$ 12 per patient. Comparison of the three centres that used HAART earliest to the three centres that used it latest showed a clear benefit to early HAART with a drop in hospitalization days by 41%, new AIDScases by 41% and deaths by 69%. The proportion of patients with HAARTrose to 27% and monthly health-care cost decreased by US$ 248 852 (i.e., by US$ 101 per patient per month). Late prescribing centres experienced a less marked effect with a drop in hospitalization days by 22%,new AIDS cases by 31%, and deaths by 32.5%. Proportion of patients with HAART rose to 12% and monthly health-care costs increased by US$ 113 578 (i.e., by US$ 38 per patient per month). Conclusions: This studysupports the extensive use of HAART in HIV-infected patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:51:31